Hims & Hers Health (NYSE:HIMS) Price Target Lowered to $21.00 at Bank of America

Hims & Hers Health (NYSE:HIMS) had its price objective cut by Bank of America from $26.00 to $21.00 in a report issued on Monday,Benzinga reports. They currently have an underperform rating on the stock.

HIMS has been the subject of a number of other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Evercore assumed coverage on Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective on the stock. Barclays started coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective on the stock. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, UBS Group set a $32.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $39.96.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $19.33 on Monday. The firm has a market cap of $4.40 billion, a price-to-earnings ratio of 35.80, a P/E/G ratio of 3.79 and a beta of 2.43. Hims & Hers Health has a 1 year low of $16.35 and a 1 year high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The business has a fifty day simple moving average of $32.60 and a 200 day simple moving average of $43.05.

Hims & Hers Health declared that its board has approved a share buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider directly owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares in the company, valued at $78,045.46. This trade represents a 79.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 129,337 shares of company stock valued at $4,651,648 in the last three months. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after buying an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the first quarter valued at about $30,000. Janney Montgomery Scott LLC increased its stake in Hims & Hers Health by 15.1% during the second quarter. Janney Montgomery Scott LLC now owns 10,019 shares of the company’s stock valued at $499,000 after acquiring an additional 1,311 shares during the period. Truist Financial Corp raised its holdings in Hims & Hers Health by 20.7% in the 2nd quarter. Truist Financial Corp now owns 9,643 shares of the company’s stock valued at $481,000 after acquiring an additional 1,656 shares in the last quarter. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Hims & Hers Health by 2.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 38,000 shares of the company’s stock worth $1,894,000 after acquiring an additional 800 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Some investors and analysts argue the market has overreacted: HIMS is not a pure GLP‑1 company, management says the oral Wegovy was pulled, and estimates (e.g., ~30% of 2025 revenue from weight‑loss) imply the business still has diversified exposure to preventative care and platform growth. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Hims announced it will stop offering the compounded semaglutide pill after the FDA signaled tighter control over compounded GLP‑1 ingredients — this removes a near‑term revenue initiative but also reduces ongoing regulatory exposure from that specific product. Hims & Hers drops plan for knockoff of Novo Nordisk’s new Wegovy weight loss pill
• Negative Sentiment: Novo Nordisk filed a patent‑infringement lawsuit seeking to block HIMS from selling compounded versions of semaglutide and to recover damages — this escalates legal risk and could lead to injunctions or settlement costs. Novo Nordisk sues Hims & Hers over patent infringement
• Negative Sentiment: Investor reaction has been severe: shares plunged with heavy volume to new lows, prompting multiple analyst cuts (Citigroup, TD Cowen, BofA) that trimmed price targets and ratings — increasing near‑term downside pressure. Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
• Negative Sentiment: Plaintiff and securities firms have opened inquiries and investor lawsuits/claims are being solicited, adding potential legal and reputational costs. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.